EyePoint Pharmaceuticals (EYPT) 10-K2014 FY Annual report

Filed: 11 Sep 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Abbvie, ACA, Acucela, advice, afibercept, antihypertensive, assumption, ATM, attention, awaiting, BCA, broad, broader, capita, cited, clarified, clarity, complement, complementary, confirmatory, conflicting, Consortium, contrast, court, cycle, Czech, Dermatologic, dialogue, disadvantage, Emixustat, escalation, facilitate, feasibility, fulfil, hired, holiday, Hydrochloride, immunotherapy, inhibit, instance, intravenously, Ireland, irrevocable, Israel, juncture, lampalizumab, Latanprost, leaking, loaded, loan, Luxembourg, MacuCLEAR, managerial, mandate, Modernization, NHS, nonstandard, Norway, notified, OncoSil, outsourced, persuade, pertinent, pipeline, Poland, pore, processor, promised, proportionate, publicly, put, referenced, refiled, refine, removed, renewal, Repair, repatriating, repealed, replace, replacement, Republic, retrospective, reuse, Scotland, Scottish, shelf, simple, solvency, sought, sovereign, STA, standby, streamline, subsidized, suggested, Suite, terrorism, threat, transfer, transition, unapplied, unexpected, untreated, unwilling, USA, usability, war, weaker, worsening, Zealand

Removed: absent, allocate, aptamer, autoimmune, bevacizumab, block, branch, cancellation, central, choroidal, coinciding, commonly, compensatory, conjunctiva, consecutive, contingent, draft, endothelial, endpoint, Eyetech, factor, fourth, honeycomb, HOPPER, increasing, insert, IRS, Latanaprost, leased, minimally, neovascular, neovascularization, Novagali, NV, originating, outpatient, PAUL, Pharma, pronouncement, prospectively, ratio, refer, reflected, reincorporated, Reincorporation, remained, retroactively, RVO, secure, shared, source, structure, studied, subgroup, sufficiently, topical, triamcinolone, underway, undesirable, unresponsive, utilize, vascular, vendor, West

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

EYPT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

In connection with the Annual Report of pSivida Corp. (the “Company”) on Form 10-K for the year ended June 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Ashton, President and Chief Executive Officer of the Company, certify that to the best of my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 11, 2014



		/S/ PAUL ASHTON
Name:		Paul Ashton
Title:		President and Chief Executive Officer (Principal Executive Officer)